Replies to post #69 on Replimune (REPL)

[jondoeuk]

It made headlines both sides of the pond. Based on the data (for RP2, as well as RP3), I'm still unsure.

Personally, I would like them to move forward with RP4 (+/- RP5), which has been engineered to secrete a next-gen anti-CTLA-4 [1] (similar to AGEN's), Flt3L (which recruits an important subset of DCs), and angiogenesis inhibitors (targeting the tumour vasculature) [4], in addition to some of the other 'payloads' they have added to RP1/2/3.

Refs:
1 https://jitc.bmj.com/content/10/1/e003488.long
2 https://www.cell.com/immunity/fulltext/S1074-7613(16)30101-7
3 https://www.nature.com/articles/s41591-019-0410-x/
4 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0095872